Good Start To 1996 For Bayer

5 May 1996

First-quarter 1996 group sales at Germany's Bayer improved 4% to 12.2 billion Deutschemarks ($7.99 billion), but this rise was almost entirely due to the first-time inclusion of ABS plastics, acquired from Monsanto. Group income before tax was up 14% at 140 million marks, and net earnings rose 19% to 110 million marks.

Health care sales, at 2.89 billion marks ($1.89 billion), were 3.1% higher in D-mark terms and showed an increase of 4.4% in local currencies. Bayer AG turnover rose 0.4% to 5.04 billion marks, and produced pretax earnings of 680 million marks, a rise of 19.2%. Within the group, particularly good sales performance was seen in North America, up 16%, while growth in Europe was just 1%. Bayer says the current year has got off to a good start; it is confident of achieving pretax earnings growth of 10% planned for the full year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight